aTyr Pharma, Inc. (NASDAQ:LIFE) Receives $19.25 Average PT from Analysts

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.25.

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Tuesday, February 7th. Roth Capital reiterated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 3rd. Royal Bank of Canada dropped their price objective on shares of aTyr Pharma from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, March 2nd. StockNews.com lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Monday, February 20th. Finally, Roth Mkm reissued a “buy” rating and set a $9.00 target price on shares of aTyr Pharma in a research report on Monday.

aTyr Pharma Trading Down 9.2 %

LIFE stock opened at $1.93 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.55 and a current ratio of 7.55. The company’s 50-day simple moving average is $2.26 and its 200 day simple moving average is $2.52. aTyr Pharma has a 52 week low of $1.90 and a 52 week high of $6.62. The company has a market capitalization of $55.99 million, a PE ratio of -1.17 and a beta of 1.23.

Institutional Trading of aTyr Pharma

Several hedge funds have recently bought and sold shares of the business. VR Adviser LLC raised its stake in aTyr Pharma by 664.8% in the 3rd quarter. VR Adviser LLC now owns 10,698,889 shares of the biotechnology company’s stock valued at $36,737,000 after acquiring an additional 9,300,000 shares during the period. Citigroup Inc. bought a new stake in aTyr Pharma in the 4th quarter valued at about $938,000. Alyeska Investment Group L.P. raised its stake in aTyr Pharma by 27.8% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,378,747 shares of the biotechnology company’s stock valued at $3,019,000 after acquiring an additional 300,000 shares during the period. Millennium Management LLC purchased a new position in aTyr Pharma during the 4th quarter valued at about $149,000. Finally, Royal Bank of Canada grew its holdings in aTyr Pharma by 8,857.2% during the 3rd quarter. Royal Bank of Canada now owns 48,727 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 48,183 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.